000			01807 a2200481 4500
005			20250516012004.0
264		0	_c20110517
008			201105s 0 0 eng d
022			_a1545-326X
024	7		_a10.1146/annurev-med-061709-145401 _2doi
040			_aNLM _beng _cNLM
100	1		_aSilva, Barbara C
245	0	0	_aNew approaches to the treatment of osteoporosis. _h[electronic resource]
260			_bAnnual review of medicine _c2011
300			_a307-22 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdaptor Proteins, Signal Transducing
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Density Conservation Agents _xtherapeutic use
650	0	4	_aBone Morphogenetic Proteins _xantagonists & inhibitors
650	0	4	_aCathepsin K _xantagonists & inhibitors
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDuodenum _xmetabolism
650	0	4	_aFemale
650	0	4	_aFractures, Bone _xprevention & control
650	0	4	_aGenetic Markers
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aOsteoporosis _xdrug therapy
650	0	4	_aParathyroid Hormone _xtherapeutic use
650	0	4	_aRANK Ligand _xantagonists & inhibitors
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSelective Estrogen Receptor Modulators _xtherapeutic use
650	0	4	_aSerotonin _xmetabolism
650	0	4	_aZoledronic Acid
700	1		_aBilezikian, John P
773	0		_tAnnual review of medicine _gvol. 62 _gp. 307-22
856	4	0	_uhttps://doi.org/10.1146/annurev-med-061709-145401 _zAvailable from publisher's website
999			_c20353001 _d20353001